Announcements

Results of Extraordinary General Meeting of Shareholders - 9 July 2021

Updated Procedures for the Upcoming EGM

VGI Health Technology (NSX:VTL) receives finished nutraceutical products in the US - 15 June 2021

Change in substantial shareholder notice for VGI Big Bang Pty Ltd - 8 June 2021

Pitt Street Research issues Initiation Report on Azure Health Technology Limited trading as VGI Health Technology (NSX:VTL) - 8 June 2021

Azure Health Technology Limited trading as VGI Health Technology appoints additional cGMP Manufacturer in US - 7 June 2021

40920 NSX Notice of Extraordinary Meeting - Extraordinary General Meeting - 4 June 2021

Extraordinary general meeting to change name of company and approve NSX compliant constitution.

Click here to download the proxy form.

Azure Health Technology Limited - Application for Quotation of Additional Securities - June 2021

Azure Health Technology Limited trading as VGI Health Technology commences trading on National Stock Exchange - 28 May 2021

Azure Health Technology Limited trading as VGI Health Technology approved to list on National Stock Exchange - 19 May 2021

Close of IPO and Name Change to VGI Health Technology Limited - 20 April 2021

Extension of Closing Date for IPO - 01 April 2021

Azure Health Technology Limited completes first manufacturing run in the US for nutraceutical products - 16 Mar 2021

AZT Announcement Replacement Prospectus and Opening of IPO - 5 Mar 2021

AZT Announcement Board Changes - 25 Feb 2021

AZT Press Release Malaysian Patent Granted - 25 Feb 2021

AZT IPO Proposed Capital Raise - 19 Feb 2021

ACCESS China Forum - An Introduction to Azure Health Technology Limited (AZT) - 21 Jan 2021

Brazilian Patent Application approved for granting - 19 Jan 2021

Azure Health Technology Limited's nutraceutical products listed on Australia's Therapeutic Goods Administration's (TGA"s) Australian Register of Therapeutic Goods (ARTG) as Listed Complementary Medicines - 18 Jan 2021

Capital Raising Update - 08 Dec 2020

Azure Health Technology Limited lodges new Australian Provisional Patent Application on Transmucosal Delivery of Tocotrienols - 07 Dec 2020

Listing Update

How to Vote Announcement

2020 AGM NOM and Proxy

2020 AGM Shareholder Q&A

Annual Report for the year ended 30 June 2020

Chinese Patent Application Granted for Transmucosal Delivery of tocotrienols - 01 October 2020

Board and Management Changes - 28 September 2020

Canadian Patent Office issues Notice of Allowance for Canadian Patent Application - 24 September 2020

Azure Health Technology completes study protocol for Pancreatic Cancer Phase II clinical study - 21 September 2020

Azure Health Technology Limited commences first manufacturing run in the US for  nutraceutical products - 24 August 2020

Azure Health Technology Completes study protocol for NAFLD/NASH Phase II clinical study - 31 July 2020

Azure Health Technology Limited appoints Non-Executive Director - 02 July 2020

Azure Health Technology Limited commences preparations for pancreatic cancer Phase II clinical study - 22 June 2020

Azure Health Technology Limited commences preparations for NAFLD/NASH Phase II clinical study - 15 June 2020

Azure Health Technology Limited acquires Invictus BioPharma Limited - 11 June 2020

Azure Health Technology Limited successfully completes Capital Raise - 03 June 2020

   ABN 35 111 082 485  

TOP